Ulcerative colitis is a chronic inflammatory disease of the colon with an increasing
incidence worldwide. The medical management of this disease continues to expand as
drugs to induce and maintain remission are sought to avoid the need for colectomy.
This article will review the standard of care for the treatment of mild, moderate,
and severe ulcerative colitis. The efficacy, optimal usage, and adverse events profile
of agents such as 5-aminosalicylates, corticosteroids, azathioprine, and cyclosporine
will be discussed and an algorithm for their use will be developed. Alternative and
experimental therapies such as monoclonal antibodies, probiotics, and heparin will
also be addressed.
KEYWORDS
Ulcerative colitis - medical therapy - cyclosporine
REFERENCES
- 1
Andres P G, Friedman L S.
Epidemiology and the natural course of inflammatory bowel disease.
Gastroenterol Clin North Am.
1999;
28
255-281
- 2
Halfvarson J, Bodin L, Tysk C, Lindberg E, Jarnerot G.
Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance
and clinical characteristics.
Gastroenterology.
2003;
124
1767-1773
- 3
Harries A D, Baird A, Rhodes J.
Non-smoking: a feature of ulcerative colitis.
Br Med J (Clin Res Ed).
1982;
284
706
- 4
Andersson R E, Olaison G, Tysk C, Ekbom A.
Appendectomy and protection against ulcerative colitis.
N Engl J Med.
2001;
344
808-814
- 5
Moum B, Vatn M H, Ekbom A et al..
Incidence of inflammatory bowel disease in southeastern Norway: evaluation of methods
after 1 year of registration. Southeastern Norway IBD Study Group of Gastroenterologists.
Digestion.
1995;
56
377-381
- 6
Langholz E, Munkholm P, Davidsen M, Binder V.
Course of ulcerative colitis: analysis of changes in disease activity over years.
Gastroenterology.
1994;
107
3-11
- 7
Langholz E, Munkholm P, Davidsen M, Nielsen O H, Binder V.
Changes in extent of ulcerative colitis: a study on the course and prognostic factors.
Scand J Gastroenterol.
1996;
31
260-266
- 8
Truelove S C, Witts L.
Cortisone in ulcerative colitis: final report on a therapeutic trial.
BMJ.
1955;
2
1041-1048
- 9
Marshall J K, Irvine E J.
Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis.
Aliment Pharmacol Ther.
1995;
9
293-300
- 10
D'Arienzo A, Panarese A, D'Armiento F P et al..
5-aminosalicylic acid suppositories in the maintenance of remission in idiopathic
proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial.
Am J Gastroenterol.
1990;
85
1079-1082
- 11
Campieri M, De Franchis R, Bianchi Porro G, Ranzi T, Brunetti G, Barbara L.
Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis
or distal proctosigmoiditis. A randomized controlled trial.
Scand J Gastroenterol.
1990;
25
663-668
- 12
Sutherland L R, Martin F, Greer S et al..
5-aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis,
and proctitis.
Gastroenterology.
1987;
92
1894-1898
- 13
d'Albasio G, Trallori G, Ghetti A et al..
Intermittent therapy with high-dose 5-aminosalicylic acid enemas for maintaining remission
in ulcerative proctosigmoiditis.
Dis Colon Rectum.
1990;
33
394-397
- 14
Svartz N.
Salazopyrine, a new sulfanilamide preparation.
Acta Med Scand.
1942;
110
557
- 15
Dick A P, Grayson M, Carpenter R G, Petrie A.
Controlled trial of sulphasalazine in the treatment of ulcerative colitis.
Gut.
1964;
50
437-442
- 16
Baron J H, Connell A, Lennard-Jones J E, Jones F A.
Sulphasalzine and salicylazosulphadimidine in ulcerative colitis.
Lancet.
1962;
1
1094-1096
- 17
Misiewicz J J, Lennard-Jones J E, Connell A M, Baron J H, Avery Jones F.
Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis.
Lancet.
1965;
1
185-188
- 18
Dissanayake A S, Truelove S C.
A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis
with sulphazalazine (Salazopyrin).
Gut.
1973;
14
923-926
- 19
Taffet S L, Das K M.
Sulfasalazine. Adverse effects and desensitization.
Dig Dis Sci.
1983;
28
833-842
- 20
O'Morain C, Smethurst P, Dore C J, Levi A J.
Reversible male infertility due to sulphasalazine: studies in man and rat.
Gut.
1984;
25
1078-1084
- 21
Das K M, Eastwood M A, McManus J P, Sircus W.
The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship
between metabolites and the response to treatment in inpatients.
Gut.
1973;
14
631-641
- 22
Klotz U, Maier K, Fischer C, Heinkel K.
Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative
colitis and Crohn's disease.
N Engl J Med.
1980;
303
1499-1502
- 23
Khan A K, Piris J, Truelove S C.
An experiment to determine the active therapeutic moiety of sulphasalazine.
Lancet.
1977;
2
892-895
- 24
Hanauer S, Schwartz J, Robinson M et al..
Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled
trial Pentasa Study Group.
Am J Gastroenterol.
1993;
88
1188-1197
- 25
Sninsky C A, Cort D H, Shanahan F et al..
Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter
study.
Ann Intern Med.
1991;
115
350-355
- 26
Schroeder K W, Tremaine W J, Ilstrup D M.
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative
colitis. A randomized study.
N Engl J Med.
1987;
317
1625-1629
- 27
Safdi M, DeMicco M, Sninsky C et al..
A double-blind comparison of oral versus rectal mesalamine versus combination therapy
in the treatment of distal ulcerative colitis.
Am J Gastroenterol.
1997;
92
1867-1871
- 28
Rao S S, Dundas S A, Holdsworth C D, Cann P A, Palmer K R, Corbett C L.
Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double-blind
study.
Gut.
1989;
30
675-679
- 29
Willoughby C P, Cowan R E, Gould S R, Machell R J, Stewart J B.
Double-blind comparison of olsalazine and sulphasalazine in active ulcerative colitis.
Scand J Gastroenterol Suppl.
1988;
148
40-44
- 30
Courtney M G, Nunes D P, Bergin C F et al..
Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative
colitis.
Lancet.
1992;
339
1279-1281
- 31
Sandberg-Gertzen H, Jarnerot G, Kraaz W.
Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention
properties.
Gastroenterology.
1986;
90
1024-1030
- 32
Meyers S, Sachar D B, Present D H, Janowitz H D.
Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant
of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging
clinical trial.
Gastroenterology.
1987;
93
1255-1262
- 33
Green J R, Lobo A J, Holdsworth C D et al..
Balsalazide is more effective and better tolerated than mesalamine in the treatment
of acute ulcerative colitis. The Abacus Investigator Group.
Gastroenterology.
1998;
114
15-22
- 34
Green J R, Mansfield J C, Gibson J A, Kerr G D, Thornton P C.
A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily,
in patients with newly diagnosed or relapsed active ulcerative colitis.
Aliment Pharmacol Ther.
2002;
16
61-68
- 35
Levine D S, Riff D S, Pruitt R et al..
A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide
(2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative
colitis.
Am J Gastroenterol.
2002;
97
1398-1407
- 36
Pruitt R, Hanson J, Safdi M et al..
Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms
of acute mild-to-moderate ulcerative colitis.
Am J Gastroenterol.
2002;
97
3078-3086
- 37
Bitton A, Peppercorn M A, Hanrahan J P, Upton M P.
Mesalamine-induced lung toxicity.
Am J Gastroenterol.
1996;
91
1039-1040
- 38
Iaquinto G, Sorrentini I, Petillo F E, Berardesca G.
Pleuropericarditis in a patient with ulcerative colitis in longstanding 5-aminosalicylic
acid therapy.
Ital J Gastroenterol.
1994;
26
145-147
- 39
Deltenre P, Berson A, Marcellin P, Degott C, Biour M, Pessayre D.
Mesalazine (5-aminosalicylic acid) induced chronic hepatitis.
Gut.
1999;
44
886-888
- 40
Fernandez J, Sala M, Panes J, Feu F, Navarro S, Teres J.
Acute pancreatitis after long-term 5-aminosalicylic acid therapy.
Am J Gastroenterol.
1997;
92
2302-2303
- 41
Brouillard M, Gheerbrant J D, Gheysens Y et al..
Chronic interstitial nephritis and mesalazine: 3 new cases? [in French].
Gastroenterol Clin Biol.
1998;
22
724-726
- 42
Hanauer S B, Verst-Brasch C, Regalli G.
Renal safety of long-term mesalamine therapy in inflammatory bowel disease (IBD).
Gastroenterology.
1997;
112
A991
- 43
Marteau P, Nelet F, Le Lu M, Devaux C.
Adverse events in patients treated with 5-aminosalicyclic acid: 1993-1994 pharmacovigilance
report for Pentasa in France.
Aliment Pharmacol Ther.
1996;
10
949-956
- 43a
Sturgeon J B, Bhatia P, Hermens D, Miner Jr P B.
Exacerbation of chronic ulcerative colitis with mesalamine.
Gastroenterology.
1995;
108
1889-1893
- 44
Edwards F, Truelove S C.
The course and prognosis of ulcerative colitis.
Gut.
1963;
41
299-315
- 45
Ekbom A, Helmick C G, Zack M, Holmberg L, Adami H O.
Survival and causes of death in patients with inflammatory bowel disease: a population-based
study.
Gastroenterology.
1992;
103
954-960
- 46
Faubion Jr W A, Loftus Jr E V, Harmsen W S, Zinsmeister A R, Sandborn W J.
The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based
study.
Gastroenterology.
2001;
121
255-260
- 47
Munkholm P, Langholz E, Davidsen M, Binder V.
Frequency of glucocorticoid resistance and dependency in Crohn's disease.
Gut.
1994;
35
360-362
- 48
Honda M, Orii F, Ayabe T et al..
Expression of glucocorticoid receptor beta in lymphocytes of patients with glucocorticoid-resistant
ulcerative colitis.
Gastroenterology.
2000;
118
859-866
- 49
Farrell R J, Murphy A, Long A et al..
High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease
patients who fail medical therapy.
Gastroenterology.
2000;
118
279-288
- 50
Baron J H, Connell A M, Kanaghinis T G, Lennard-Jones J E, Jones A F.
Out-patient treatment of ulcerative colitis. Comparison between three doses of oral
prednisone.
BMJ.
1962;
5302
441-443
- 51
Powell-Tuck J, Bown R L, Lennard-Jones J E.
A comparison of oral prednisolone given as single or multiple daily doses for active
proctocolitis.
Scand J Gastroenterol.
1978;
13
833-837
- 52
Lennard-Jones J E, Misiewicz J J, Connell A M, Baron J H, Avery Jones F.
Prednisone as maintenance treatment for ulcerative colitis in remission.
Lancet.
1965;
191
188-189
- 53
Watkinson G.
Treatment of ulcerative colitis with topical hydrocortisone hemisuccinate sodium A
controlled trial employing restricted sequential analysis.
BMJ.
1958;
1077-1082
- 54
Lennard-Jones J E, Baron J H, Connell A M et al..
A double blind controlled trial of prednisolone-21-phosphate suppositories in the
treatment of idiopathic proctitis.
Gut.
1962;
3
207-210
- 55
Truelove S.
Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium. A
report on a controlled therapeutic trial.
BMJ.
1958;
1072-1077
- 56
Lindgren S, Lofberg R, Bergholm L et al..
Effect of budesonide enema on remission and relapse rate in distal ulcerative colitis
and proctitis.
Scand J Gastroenterol.
2002;
37
705-710
- 57
Cohen R D, Woseth D M, Thisted R A, Hanauer S B.
A meta-analysis and overview of the literature on treatment options for left-sided
ulcerative colitis and ulcerative proctitis.
Am J Gastroenterol.
2000;
95
1263-1276
- 58
Farmer R G, Schumacher O P.
Treatment of ulcerative colitis with hydrocortisone enemas. Comparison of absorption
and clinical response with hydrocortisone alcohol and hydrocortisone acetate.
Am J Gastroenterol.
1970;
54
229-236
- 59
Elliott P R, Powell-Tuck J, Gillespie P E et al..
Prednisolone absorption in acute colitis.
Gut.
1980;
21
49-51
- 60
Truelove S C, Jewell D P.
Intensive intravenous regimen for severe attacks of ulcerative colitis.
Lancet.
1974;
1
1067-1070
- 61
Rizzello F, Gionchetti P, Venturi A, Campieri M.
Medical treatment of severe ulcerative colitis.
Aliment Pharmacol Ther.
2003;
17(suppl 2)
7-10
- 62
Meyers S, Sachar D B, Goldberg J D, Janowitz H D.
Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis.
A prospective, randomized, double-blind clinical trial.
Gastroenterology.
1983;
85
351-357
- 63
Powell-Tuck J, Buckell N A, Lennard-Jones J E.
A controlled comparison of corticotropin and hydrocortisone in the treatment of severe
proctocolitis.
Scand J Gastroenterol.
1977;
12
971-975
- 64
Kaplan H P, Portnoy B, Binder H J, Amatruda T, Spiro H.
A controlled evaluation of intravenous adrenocorticotropic hormone and hydrocortisone
in the treatment of acute colitis.
Gastroenterology.
1975;
69
91-95
- 65
Talar-Williams C, Sneller M C.
Complications of corticosteroid therapy.
Eur Arch Otorhinolaryngol.
1994;
251
131-136
- 66
Singleton J W, Law D H, Kelley Jr M L, Mekhjian H S, Sturdevant R A.
National Cooperative Crohn's Disease Study: adverse reactions to study drugs.
Gastroenterology.
1979;
77
870-882
- 67
Kusunoki M, Moeslein G, Shoji Y et al..
Steroid complications in patients with ulcerative colitis.
Dis Colon Rectum.
1992;
35
1003-1009
- 68
Turunen U M, Farkkila M A, Hakala K et al..
Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind,
placebo-controlled study.
Gastroenterology.
1998;
115
1072-1078
- 69
Mantzaris G J, Archavlis E, Christoforidis P et al..
A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative
colitis.
Am J Gastroenterol.
1997;
92
454-456
- 70
Mantzaris G J, Petraki K, Archavlis E et al..
A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct
to corticosteroids in acute, severe ulcerative colitis.
Scand J Gastroenterol.
2001;
36
971-974
- 71
Burke D A, Axon A T, Clayden S A, Dixon M F, Johnston D, Lacey R W.
The efficacy of tobramycin in the treatment of ulcerative colitis.
Aliment Pharmacol Ther.
1990;
4
123-129
- 72
Lobo A J, Burke D A, Sobala G M, Axon A T.
Oral tobramycin in ulcerative colitis: effect on maintenance of remission.
Aliment Pharmacol Ther.
1993;
7
155-158
- 73
Mantzaris G J, Hatzis A, Kontogiannis P, Triadaphyllou G.
Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute,
severe ulcerative colitis.
Am J Gastroenterol.
1994;
89
43-46
- 74
Dickinson R J, O'Connor H J, Pinder I, Hamilton I, Johnston D, Axon A T.
Double blind controlled trial of oral vancomycin as adjunctive treatment in acute
exacerbations of idiopathic colitis.
Gut.
1985;
26
1380-1384
- 75
Chapman R W, Selby W S, Jewell D P.
Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in
severe ulcerative colitis.
Gut.
1986;
27
1210-1212
- 76
Gionchetti P, Rizzello F, Ferrieri A et al..
Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment:
a double-blind, placebo-controlled trial.
Dig Dis Sci.
1999;
44
1220-1221
- 77
Gionchetti P, Rizzello F, Helwig U et al..
Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled
trial.
Gastroenterology.
2003;
124
1202-1209
- 78
Gionchetti P, Rizzello F, Venturi A et al..
Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis:
a double-blind, placebo-controlled trial.
Gastroenterology.
2000;
119
305-309
- 79
Rembacken B J, Snelling A M, Hawkey P M, Chalmers D M, Axon A T.
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.
Lancet.
1999;
354
635-639
- 80
Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M.
Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis.
Aliment Pharmacol Ther.
1997;
11
853-858
- 81
Fedorak R, Gionchetti P, Campieri M, Madsen K, Isaacs K.
VSL3 probiotic mixture induces remission in patients with active ulcerative colitis.
Gastroenterology.
2003;
124
A-377
- 82
Beaugerie L, Massot N, Carbonnel F, Cattan S, Gendre J P, Cosnes J.
Impact of cessation of smoking on the course of ulcerative colitis.
Am J Gastroenterol.
2001;
96
2113-2116
- 83
Green J T, Richardson C, Marshall R W et al..
Nitric oxide mediates a therapeutic effect of nicotine in ulcerative colitis.
Aliment Pharmacol Ther.
2000;
14
1429-1434
- 84
Sandborn W J.
Nicotine therapy for ulcerative colitis: a review of rationale, mechanisms, pharmacology,
and clinical results.
Am J Gastroenterol.
1999;
94
1161-1171
- 85
Pullan R D, Rhodes J, Ganesh S et al..
Transdermal nicotine for active ulcerative colitis.
N Engl J Med.
1994;
330
811-815
- 86
Sandborn W J, Tremaine W J, Offord K P et al..
Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized,
double-blind, placebo-controlled trial.
Ann Intern Med.
1997;
126
364-371
- 87
Thomas G A, Rhodes J, Mani V et al..
Transdermal nicotine as maintenance therapy for ulcerative colitis.
N Engl J Med.
1995;
332
988-992
- 88
Guslandi M.
Long-term effects of a single course of nicotine treatment in acute ulcerative colitis:
remission maintenance in a 12-month follow-up study.
Int J Colorectal Dis.
1999;
14
261-262
- 89
Green J T, Thomas G A, Rhodes J et al..
Nicotine enemas for active ulcerative colitis-a pilot study.
Aliment Pharmacol Ther.
1997;
11
859-863
- 90
Sandborn W J, Tremaine W J, Leighton J A et al..
Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative
colitis unresponsive to first-line therapy: a pilot study.
Aliment Pharmacol Ther.
1997;
11
663-671
- 91
Bean R.
The treatment of chronic ulcerative colitis with 6-mercaptopurine.
Med J Aust.
1962;
49
592-593
- 92
Jewell D P, Truelove S C.
Azathioprine in ulcerative colitis: final report on controlled therapeutic trial.
BMJ.
1974;
4
627-630
- 93
Kirk A P, Lennard-Jones J E.
Controlled trial of azathioprine in chronic ulcerative colitis.
Br Med J (Clin Res Ed).
1982;
284
1291-1292
- 94
Hawthorne A B, Logan R F, Hawkey C J et al..
Randomised controlled trial of azathioprine withdrawal in ulcerative colitis.
BMJ.
1992;
305
20-22
- 95
Ardizzone S, Molteni P, Imbesi V, Bollani S, Bianchi Porro G, Molteni F.
Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis.
J Clin Gastroenterol.
1997;
25
330-333
- 96
Lobo A J, Foster P N, Burke D A, Johnston D, Axon A T.
The role of azathioprine in the management of ulcerative colitis.
Dis Colon Rectum.
1990;
33
374-377
- 97
Steinhart A H, Baker J P, Brzezinski A, Prokipchuk E J.
Azathioprine therapy in chronic ulcerative colitis.
J Clin Gastroenterol.
1990;
12
271-275
- 98
Korelitz B I, Adler D J, Mendelsohn R A, Sacknoff A L.
Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease.
Am J Gastroenterol.
1993;
88
1198-1205
- 99
George J, Present D H, Pou R, Bodian C, Rubin P H.
The long-term outcome of ulcerative colitis treated with 6-mercaptopurine.
Am J Gastroenterol.
1996;
91
1711-1714
- 100
Pearson D C, May G R, Fick G H, Sutherland L R.
Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis.
Ann Intern Med.
1995;
123
132-142
- 101
Mahadevan U, Tremaine W J, Johnson T et al..
Intravenous azathioprine in severe ulcerative colitis: a pilot study.
Am J Gastroenterol.
2000;
95
3463-3468
- 102
Black A J, McLeod H L, Capell H A et al..
Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from
azathioprine.
Ann Intern Med.
1998;
129
716-718
- 103
Colombel J F, Ferrari N, Debuysere H et al..
Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease
and severe myelosuppression during azathioprine therapy.
Gastroenterology.
2000;
118
1025-1030
- 104
Snow J L, Gibson L E.
A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine
drugs in dermatologic patients.
J Am Acad Dermatol.
1995;
32
114-116
- 105
Dubinsky M C, Lamothe S, Yang H Y et al..
Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory
bowel disease.
Gastroenterology.
2000;
118
705-713
- 106
Cuffari C, Theoret Y, Latour S, Seidman G.
6-mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity.
Gut.
1996;
39
401-406
- 107
Lowry P W, Franklin C L, Weaver A L et al..
Measurement of thiopurine methyltransferase activity and azathioprine metabolites
in patients with inflammatory bowel disease.
Gut.
2001;
49
665-670
- 108
Belaiche J, Desager J P, Horsmans Y, Louis E.
Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn's
disease.
Scand J Gastroenterol.
2001;
36
71-76
- 109
Sandborn W J, Tremaine W J, Wolf D C et al..
Lack of effect of intravenous administration on time to respond to azathioprine for
steroid-treated Crohn's disease North American Azathioprine Study Group.
Gastroenterology.
1999;
117
527-535
- 110
Present D H, Meltzer S J, Krumholz M P, Wolke A, Korelitz B I.
6-mercaptopurine in the management of inflammatory bowel disease: short- and long-term
toxicity.
Ann Intern Med.
1989;
111
641-649
- 111
Connell W R, Kamm M A, Dickson M, Balkwill A M, Ritchie J K, Lennard-Jones J E.
Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease.
Lancet.
1994;
343
1249-1252
- 112
Fraser A G, Orchard T R, Robinson E M, Jewell D P.
Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine.
Aliment Pharmacol Ther.
2002;
16
1225-1232
- 113
Dayharsh G A, Loftus Jr E V, Sandborn W J et al..
Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated
with azathioprine or 6-mercaptopurine.
Gastroenterology.
2002;
122
72-77
- 114
Feagan B G, Fedorak R N, Irvine E J et al..
A comparison of methotrexate with placebo for the maintenance of remission in Crohn's
disease. North American Crohn's Study Group Investigators.
N Engl J Med.
2000;
342
1627-1632
- 115
Feagan B G, Rochon J, Fedorak R N et al..
Methotrexate for the treatment of Crohn's disease. North American Crohn's Study Group
Investigators.
N Engl J Med.
1995;
332
292-297
- 116
Egan L J, Tremaine W J, Mays D C, Lipsky J J, Sandborn W J.
Clinical outcome and pharmacokinetics after addition of low-dose cyclosporine to methotrexate:
a case study of five patients with treatment-resistant inflammatory bowel disease.
Inflamm Bowel Dis.
2000;
6
286-289
- 117
Baron T H, Truss C D, Elson C O.
Low-dose oral methotrexate in refractory inflammatory bowel disease.
Dig Dis Sci.
1993;
38
1851-1856
- 118
Kozarek R A, Patterson D J, Gelfand M D, Botoman V A, Ball T J, Wilske K R.
Methotrexate induces clinical and histologic remission in patients with refractory
inflammatory bowel disease.
Ann Intern Med.
1989;
110
353-356
- 119
Oren R, Arber N, Odes S et al..
Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli
multicenter trial.
Gastroenterology.
1996;
110
1416-1421
- 120
Paoluzi O A, Pica R, Marcheggiano A et al..
Azathioprine or methotrexate in the treatment of patients with steroid-dependent or
steroid-resistant ulcerative colitis: results of an open-label study on efficacy and
tolerability in inducing and maintaining remission.
Aliment Pharmacol Ther.
2002;
16
1751-1759
- 121
Lichtiger S, Present D H, Kornbluth A et al..
Cyclosporine in severe ulcerative colitis refractory to steroid therapy.
N Engl J Med.
1994;
330
1841-1845
- 122
Svanoni F, Bonassi U, Bagnolo F et al..
Effectiveness of cyclosporoine A (CsA) in the treatment of active refractory ulcerative
colitis.
Gastroenterology.
1998;
114
A1096
- 123
D'Haens G, Lemmens L, Geboes K et al..
Intravenous cyclosporine versus intravenous corticosteroids as single therapy for
severe attacks of ulcerative colitis.
Gastroenterology.
2001;
120
1323-1329
- 124
Van Assche G, D'Haens G, Noman M et al..
Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine
in severe ulcerative colitis.
Gastroenterology.
2003;
125
1025-1031
- 125
Kornbluth A, Present D H, Lichtiger S, Hanauer S.
Cyclosporin for severe ulcerative colitis: a user's guide.
Am J Gastroenterol.
1997;
92
1424-1428
- 126
Cohen R D, Stein R, Hanauer S B.
Intravenous cyclosporin in ulcerative colitis: a five-year experience.
Am J Gastroenterol.
1999;
94
1587-1592
- 127
Domenech E, Garcia-Planella E, Bernal I et al..
Azathioprine without oral ciclosporin in the long-term maintenance of remission induced
by intravenous ciclosporin in severe, steroid-refractory ulcerative colitis.
Aliment Pharmacol Ther.
2002;
16
2061-2065
- 128
Sandborn W J.
Cyclosporine in ulcerative colitis: state of the art.
Acta Gastroenterol Belg.
2001;
64
201-204
- 129
Latteri M, Angeloni T G, Silveri N G, Manna R, Gasbarrini G, Navarra P.
Pharmacokinetics of cyclosporin microemulsion in patients with inflammatory bowel
disease.
Clin Pharmacokinet.
2001;
40
473-483
- 130
Actis G C, Aimo G, Priolo G, Moscato D, Rizzetto M, Pagni R.
Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft
gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative
colitis: an open-label retrospective trial.
Inflamm Bowel Dis.
1998;
4
276-279
- 131
Navazo L, Salata H, Morales S et al..
Oral microemulsion cyclosporine in the treatment of steroid-refractory attacks of
ulcerative and indeterminate colitis.
Scand J Gastroenterol.
2001;
36
610-614
- 132
Sood A, Midha V, Sood N.
Oral cyclosporine in patients with active severe ulcerative colitis not responding
to steroids.
Indian J Gastroenterol.
2002;
21
155-156
- 133
Sternthal M GJ, Kornbluth A.
Toxicity associated with the use of cyclosporin in patients with inflammatory bowel
disease.
Gastroenterology.
1996;
110
A1019
- 134
Bousvaros A, Kirschner B S, Werlin S L et al..
Oral tacrolimus treatment of severe colitis in children.
J Pediatr.
2000;
137
794-799
- 135
Baumgart D C, Wiedenmann B, Dignass A U.
Rescue therapy with tacrolimus is effective in patients with severe and refractory
inflammatory bowel disease.
Aliment Pharmacol Ther.
2003;
17
1273-1281
- 136
Matsuhashi N, Nakajima A, Watanabe K et al..
Tacrolimus in corticosteroid-resistant ulcerative colitis.
J Gastroenterol.
2000;
35
635-640
- 137
Pascu M, Muller A R, Wiedenmann B, Dignass A U.
Rescue therapy with tacrolimus in a patient with toxic megacolon.
Int J Colorectal Dis.
2003;
18
271-275
- 138
Fellermann K, Tanko Z, Herrlinger K R et al..
Response of refractory colitis to intravenous or oral tacrolimus (FK506).
Inflamm Bowel Dis.
2002;
8
317-324
- 139
Hanauer S LG, Colombel J F et al..
Maintenance infliximab (Remicade) is safe, effective and steroid-sparing in Crohn's
disease: preliminary results of the Accent I trial.
Gastroenterology.
2001;
120
A-21
- 140
Sands B E, Tremaine W J, Sandborn W J et al..
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot
study.
Inflamm Bowel Dis.
2001;
7
83-88
- 141
Chey W Y, Hussain A, Ryan C, Potter G D, Shah A.
Infliximab for refractory ulcerative colitis.
Am J Gastroenterol.
2001;
96
2373-2381
- 142
Kaser A, Mairinger T, Vogel W, Tilg H.
Infliximab in severe steroid-refractory ulcerative colitis: a pilot study.
Wien Klin Wochenschr.
2001;
113
930-933
- 143
Probert C, Hearing S D, Shreiber S, Kuhbacher T, Ghosh S, Forbes A.
Infliximab in steroid-resistant ulcerative colitis: a randomized controlled trial.
Gastroenterology.
2002;
122
A-99
- 144
Ochsenkuhn T, Sackmann M, Goeke B.
Infliximab for acute severe uclerative colitis: a randomized pilot study in nonsteroid
refractory patients.
Gastroenterology.
2003;
124
A62
- 145
Su C, Salzberg B A, Lewis J D et al..
Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis.
Am J Gastroenterol.
2002;
97
2577-2584
- 146
Dhillon A P, Anthony A, Sim R et al..
Mucosal capillary thrombi in rectal biopsies.
Histopathology.
1992;
21
127-133
- 147
Gaffney P R, Doyle C T, Gaffney A, Hogan J, Hayes D P, Annis P.
Paradoxical response to heparin in 10 patients with ulcerative colitis.
Am J Gastroenterol.
1995;
90
220-223
- 148
Evans R C, Wong V S, Morris A I, Rhodes J M.
Treatment of corticosteroid-resistant ulcerative colitis with heparin-a report of
16 cases.
Aliment Pharmacol Ther.
1997;
11
1037-1040
- 149
Panes J, Esteve M, Cabre E et al..
Comparison of heparin and steroids in the treatment of moderate and severe ulcerative
colitis.
Gastroenterology.
2000;
119
903-908
- 150
Ang Y S, Mahmud N, White B et al..
Randomized comparison of unfractionated heparin with corticosteroids in severe active
inflammatory bowel disease.
Aliment Pharmacol Ther.
2000;
14
1015-1022
- 151
Bloom S, Kiilerich S, Lassen M R, O'Morain C, Forbes A, Orm S.
Randomized trial of tinzaparin, a low molecular weight heparin (LMWH), versus placebo
in the treatment of mild to moderately active ulcerative colitis.
Gastroenterology.
2003;
124
A67
- 152
Korzenik J, Miner P, Stanton D et al..
Multicenter, randomized, double-blind, placebo-controlled trial of Deligoparin (ultra
low molecular weight heparin) for active ulcerative colitis.
Gastroenterology.
2003;
124
A67
- 153
Tuvlin J A, Kane S V.
Novel therapies in the treatment of ulcerative colitis.
Expert Opin Investig Drugs.
2003;
12
483-490
- 154
Creed T, Hearing S, Probert C, Norman M, Dayan C.
Basiliximab (IL-2 receptor antagonist) as a steroid sensitizing.
Gastroenterology.
2003;
124
A7
- 155
Plevy S, Salzberg B A, Regueiro M et al..
A humanized anti-CD3 monoclonal antibody, visilizumab, for treatment of severe steroid-refractory
ulcerative colitis: preliminary results of a phase I study.
Gastroenterology.
2003;
124
A7
- 156
Feagan B, Greenberg G, Wild G et al..
A randomized controlled trial of a humanized α4β7 antibody in ulcerative colitis.
Gastroenterology.
2003;
124:Abstract
- 157
Musch E, Raedler A, Andus T et al..
A phase II placebo-controlled, randomized, multicenter study to evaluate efficacy
and safety of interferon beta-1a in patients with ulcerative colitis.
Gastroenterology.
2002;
122
A431
- 158
Sawada K, Ohnishi K, Fukui S et al..
Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory
bowel disease.
J Gastroenterol.
1995;
30
322-329
- 159
Sawada K, Muto T, Shimoyama T et al..
Multicenter randomized controlled trial for the treatment of ulcerative colitis with
a leukocytapheresis column.
Curr Pharm Des.
2003;
9
307-321
- 160
Sawada K, Kusugam K, Suzuki Y.
Multicenter randomized double blind controlled trial for ulcerative colitis therapy
with leukocytapheresis.
Gastroenterology.
2003;
124
A67
- 161
Cottone M, Pietrosi G, Martorana G et al..
Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's
colitis.
Am J Gastroenterol.
2001;
96
773-775
- 162
Mahadevan U, Loftus Jr E V, Tremaine W J et al..
Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated
with increased postoperative complications.
Inflamm Bowel Dis.
2002;
8
311-316
- 163
Yang Y X, Lichtenstein G R.
Corticosteroids in Crohn's disease.
Am J Gastroenterol.
2002;
97
803-823
Uma MahadevanM.D.
UCSF/Mount Zion IBD Center
2330 Post Street #610
San Francisco, CA 94115
eMail: umamah@itsa.ucsf.edu